CIP
NBIX icon

Chartwell Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

Chartwell Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,086
Closed -$691K – 426
2022
Q2 		$691K Buy
7,086
+106
+2% +$9.78K 0.03% 379
2022
Q1 		$654K Buy
6,980
+408
+6% +$34.6K 0.02% 396
2021
Q4 		$560K Hold
6,572
– – 0.02% 406
2021
Q3 		$630K Sell
6,572
-15,271
-70% -$1.44M 0.02% 403
2021
Q2 		$2.13M Sell
21,843
-14
-0.1% -$1.34K 0.06% 287
2021
Q1 		$2.13M Sell
21,857
-2,175
-9% -$228K 0.06% 276
2020
Q4 		$2.3M Buy
24,032
+214
+0.9% +$20.7K 0.07% 266
2020
Q3 		$2.29M Buy
23,818
+4,918
+26% +$569K 0.08% 255
2020
Q2 		$2.31M Buy
18,900
+12,782
+209% +$1.41M 0.09% 254
2020
Q1 		$530K Sell
6,118
-300
-5% -$29.4K 0.02% 364
2019
Q4 		$690K Hold
6,418
– – 0.02% 374
2019
Q3 		$578K Sell
6,418
-182
-3% -$17K 0.02% 386
2019
Q2 		$557K Sell
6,600
-1,507
-19% -$124K 0.02% 394
2019
Q1 		$714K Buy
8,107
+413
+5% +$34.5K 0.02% 400
2018
Q4 		$549K Sell
7,694
-362
-4% -$34.7K 0.02% 424
2018
Q3 		$990K Sell
8,056
-33,122
-80% -$3.76M 0.03% 442
2018
Q2 		$4.04M Sell
41,178
-20,081
-33% -$1.8M 0.12% 230
2018
Q1 		$5.08M Sell
61,259
-1,023
-2% -$86.4K 0.17% 184
2017
Q4 		$4.83M Sell
62,282
-11,146
-15% -$760K 0.16% 203
2017
Q3 		$4.5M Buy
73,428
+3,532
+5% +$186K 0.15% 204
2017
Q2 		$3.21M Buy
69,896
+3,992
+6% +$194K 0.12% 231
2017
Q1 		$2.85M Sell
65,904
-80,108
-55% -$3.43M 0.1% 240
2016
Q4 		$5.65M Buy
146,012
+24,057
+20% +$1.09M 0.19% 170
2016
Q3 		$6.18M Buy
+121,955
New +$6.07M 0.11% 225

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Chartwell Investment Partners's NBIX Position: Q3 2022 in Review

Chartwell Investment Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 7,086 shares — an estimated $691K sold.

Chartwell Investment Partners first reported a position in NBIX in Q3 2016 and held it in 24 quarters. The position peaked at $6.18M in Q3 2016. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • Chartwell Investment Partners reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 7,086 Neurocrine Biosciences shares in Q3 2022, an estimated $691K.
  • Chartwell Investment Partners first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 24 quarters.
  • Chartwell Investment Partners's Neurocrine Biosciences position peaked at $6.18M in Q3 2016.
  • 466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Chartwell Investment Partners's 13F filing for Q3 2022, filed 27 Oct 2022.